AAAAAA

   
Results: 1-25 | 26-26
Results: 1-25/26
EFFECTS OF PRAMLINTIDE THERAPY - A 1-YEAR STUDY IN INSULIN-REQUIRING TYPE-2 DIABETES
Authors: RATNER R LEVETAN C SCHOENFELD S JEFFCOATE S KOLTERMAN O
Citation: R. Ratner et al., EFFECTS OF PRAMLINTIDE THERAPY - A 1-YEAR STUDY IN INSULIN-REQUIRING TYPE-2 DIABETES, Diabetologia, 41, 1998, pp. 233-233
POSITIVE EFFECTS ON BODY-WEIGHT RESULTING FROM PRAMLINTIDE THERAPY INTYPE-1 AND TYPE-3 DIABETES
Authors: KOLTERMAN O WHITEHOUSE F RATNER R ROSENSTOCK J SCHOENFELD S JEFFCOATE S
Citation: O. Kolterman et al., POSITIVE EFFECTS ON BODY-WEIGHT RESULTING FROM PRAMLINTIDE THERAPY INTYPE-1 AND TYPE-3 DIABETES, Diabetologia, 41, 1998, pp. 830-830
RESULTS OF 1-YEAR STUDY WITH PRAMLINTIDE THERAPY IN TYPE-1 DIABETES -EFFECT ON METABOLIC CONTROL AND SAFETY PROFILE
Authors: ROSENSTOCK J WHITEHOUSE F SCHOENFELD S JEFFCOATE S KOLTERMAN O
Citation: J. Rosenstock et al., RESULTS OF 1-YEAR STUDY WITH PRAMLINTIDE THERAPY IN TYPE-1 DIABETES -EFFECT ON METABOLIC CONTROL AND SAFETY PROFILE, Diabetologia, 41, 1998, pp. 925-925
PRAMLINTIDE SHOWED POSITIVE EFFECTS ON BODY-WEIGHT IN TYPE-1 AND TYPE-2 DIABETES
Authors: WHITEHOUSE F RATNER R ROSENSTOCK J SCHOENFELD S KOLTERMAN O
Citation: F. Whitehouse et al., PRAMLINTIDE SHOWED POSITIVE EFFECTS ON BODY-WEIGHT IN TYPE-1 AND TYPE-2 DIABETES, Diabetes, 47, 1998, pp. 35-35
PRAMLINTIDE THERAPY IN THE TREATMENT OF INSULIN-REQUIRING TYPE-2 DIABETES - RESULTS OF A 1-YEAR PLACEBO-CONTROLLED TRIAL
Authors: RATNER R LEVETAN C SHOENFELD S ORGAN K KOLTERMAN O
Citation: R. Ratner et al., PRAMLINTIDE THERAPY IN THE TREATMENT OF INSULIN-REQUIRING TYPE-2 DIABETES - RESULTS OF A 1-YEAR PLACEBO-CONTROLLED TRIAL, Diabetes, 47, 1998, pp. 341-341
EFFECT OF PRAMLINTIDE ON METABOLIC CONTROL AND SAFETY PROFILE IN PEOPLE WITH TYPE-1 DIABETES
Authors: ROSENSTOCK J WHITEHOUSE F SCHOENFELD S DEAN E BLONDE L KOLTERMAN O
Citation: J. Rosenstock et al., EFFECT OF PRAMLINTIDE ON METABOLIC CONTROL AND SAFETY PROFILE IN PEOPLE WITH TYPE-1 DIABETES, Diabetes, 47, 1998, pp. 342-342
SUBCUTANEOUS ADMINISTRATION OF A HUMAN AMYLIN ANALOG SUPPRESSES POSTPRANDIAL PLASMA-GLUCAGON CONCENTRATIONS IN TYPE-1 DIABETIC-PATIENTS
Authors: FINEMAN M KODA J KOLTERMAN O
Citation: M. Fineman et al., SUBCUTANEOUS ADMINISTRATION OF A HUMAN AMYLIN ANALOG SUPPRESSES POSTPRANDIAL PLASMA-GLUCAGON CONCENTRATIONS IN TYPE-1 DIABETIC-PATIENTS, Diabetes, 47, 1998, pp. 346-346
EFFECTS OF THE AMYLIN ANALOG PRAMLINTIDE ON THE GLUCOSE RESPONSE TO AGLUCAGON CHALLENGE IN IDDM
Authors: ORSKOV L NYHOLM B HOVE KY GRAVHOLT CH MOLLER N KOLTERMAN O ALBERTI KGMM SCHMITZ O
Citation: L. Orskov et al., EFFECTS OF THE AMYLIN ANALOG PRAMLINTIDE ON THE GLUCOSE RESPONSE TO AGLUCAGON CHALLENGE IN IDDM, Diabetologia, 40, 1997, pp. 1396-1396
PRAMLINTIDE IMPROVES GLYCEMIC CONTROL IN PATIENTS WITH TYPE-II DIABETES REQUIRING INSULIN
Authors: THOMPSON R PEARSON L SCHOENFELD S KOLTERMAN O
Citation: R. Thompson et al., PRAMLINTIDE IMPROVES GLYCEMIC CONTROL IN PATIENTS WITH TYPE-II DIABETES REQUIRING INSULIN, Diabetologia, 40, 1997, pp. 1397-1397
PRAMLINTIDE, AN ANALOG OF HUMAN AMYLIN IMPROVES GLYCEMIC CONTROL IN PATIENTS WITH TYPE-II DIABETES REQUIRING INSULIN
Authors: THOMPSON R PEARSON L SCHOENFELD S KOLTERMAN O
Citation: R. Thompson et al., PRAMLINTIDE, AN ANALOG OF HUMAN AMYLIN IMPROVES GLYCEMIC CONTROL IN PATIENTS WITH TYPE-II DIABETES REQUIRING INSULIN, Diabetes, 46, 1997, pp. 116-116
THE HUMAN AMYLIN ANALOG PRAMLINTIDE INHIBITED GLUCAGON-SECRETION IN TYPE-I DIABETIC SUBJECTS
Authors: FINEMAN M KOLTERMAN O THOMPSON R KODA J
Citation: M. Fineman et al., THE HUMAN AMYLIN ANALOG PRAMLINTIDE INHIBITED GLUCAGON-SECRETION IN TYPE-I DIABETIC SUBJECTS, Diabetes, 46, 1997, pp. 117-117
EFFECTS OF THE AMYLIN ANALOG PRAMLINTIDE ON THE GLUCOSE RESPONSE TO AGLUCAGON CHALLENGE IN IDDM
Authors: ORSKOV L NYHOLM B HOVE K GRAVHOLT CH MOLLER N KOLTERMAN O ALBERTI K SCHMITZ O
Citation: L. Orskov et al., EFFECTS OF THE AMYLIN ANALOG PRAMLINTIDE ON THE GLUCOSE RESPONSE TO AGLUCAGON CHALLENGE IN IDDM, Diabetes, 46, 1997, pp. 597-597
MODULATION OF GASTRIC-EMPTYING AS A THERAPEUTIC APPROACH TO GLYCEMIC CONTROL
Authors: MOYSES C YOUNG A KOLTERMAN O
Citation: C. Moyses et al., MODULATION OF GASTRIC-EMPTYING AS A THERAPEUTIC APPROACH TO GLYCEMIC CONTROL, Diabetic medicine, 13(9), 1996, pp. 34-38
EFFECT OF RACE AND HYPERTENSION ON PLASMA AMYLIN CONCENTRATIONS
Authors: DIMSDALE JE KOLTERMAN O KODA J NELESEN R
Citation: Je. Dimsdale et al., EFFECT OF RACE AND HYPERTENSION ON PLASMA AMYLIN CONCENTRATIONS, Hypertension, 27(6), 1996, pp. 1273-1276
A DOSE-RESPONSE STUDY OF GLIMEPIRIDE IN PATIENTS WITH NIDDM WHO HAVE PREVIOUSLY RECEIVED SULFONYLUREA AGENTS
Authors: GOLDBERG RB HOLVEY SM SCHNEIDER J BANSAL S BLONDE L BODEN G BRANSOME ED CLARK C CLARKE D DAVIS M DAVIS S GERICH J GOLDBERG R HAAG B HENDLER R JOSSE RG JOVANOVICPETERSON L KARAM JH KENNEDY F KILO C KLACHKO D KNOPF RF KOLTERMAN O KROSNICK A LEITER LA LESLIE C MALONE JK MEENAN A METZGER B MORRISON AD RASKIN P REEVES M RENDELL M SAUDEK C SCHWARTZ S SKOR D TUNG PC
Citation: Rb. Goldberg et al., A DOSE-RESPONSE STUDY OF GLIMEPIRIDE IN PATIENTS WITH NIDDM WHO HAVE PREVIOUSLY RECEIVED SULFONYLUREA AGENTS, Diabetes care, 19(8), 1996, pp. 849-856
SELF-CARE PRACTICES AND OUTCOMES IN THE DCCT COHORT 2 YEARS POST-COMPLETION - EDIC FOLLOW-UP-STUDY
Authors: KOLTERMAN O LORENZI G
Citation: O. Kolterman et G. Lorenzi, SELF-CARE PRACTICES AND OUTCOMES IN THE DCCT COHORT 2 YEARS POST-COMPLETION - EDIC FOLLOW-UP-STUDY, Diabetes, 45, 1996, pp. 455-455
PRAMLINTIDE, AN ANALOG OF HUMAN AMYLIN, REDUCED FRUCTOSAMINE IN PATIENTS WITH TYPE-I DIABETES
Authors: THOMPSON RG PEARSON L GOTTLIEB A KOLTERMAN O
Citation: Rg. Thompson et al., PRAMLINTIDE, AN ANALOG OF HUMAN AMYLIN, REDUCED FRUCTOSAMINE IN PATIENTS WITH TYPE-I DIABETES, Diabetes, 45, 1996, pp. 818-818
RAMLINTIDE, A HUMAN AMYLIN ANALOG, IMPROVED GLUCOSE CONTROL INDEPENDENT OF ENTRY HBA1C
Authors: KOLTERMAN O PEARSON L PETERSON J GOTTLIEB A THOMPSON R
Citation: O. Kolterman et al., RAMLINTIDE, A HUMAN AMYLIN ANALOG, IMPROVED GLUCOSE CONTROL INDEPENDENT OF ENTRY HBA1C, Diabetes, 45, 1996, pp. 1072-1072
IMPLEMENTATION OF TREATMENT PROTOCOLS IN THE DIABETES CONTROL AND COMPLICATIONS TRIAL
Authors: SHAMOON H DUFFY H FLEISCHER N ENGEL S SAENGER P STRELYZN M LITWAK M WYLIEROSETT J FARKASH A GEIGER D ENGEL H FLEISCHMAN J POMPI D GINSBERG N GLOVER M BRISMAN M WALKER E THOMASUNIS A GONZALEZ J GENUTH S DAHMS W BROWN E PUGSLEY P MAYER L KERR D LANDAU B SINGERMAN L RICE T NOVAK M SMITHBREWER S MCCONNELL J DROTAR D WOODS D LITVENE M KATIRJI B BROWN C CAMPBELL R RICHARSON M LACKAYE M LEVY B CHANG S HEINHEINEMANN M BARRON S ASTOR L LEBECK D BRILLON D DIAMOND B VASILASDWOSKIN A LAURENZI B FOLDI N RUBIN M WHITEHOUSE F KAHKONEN D KRUGER D FACHNIE J FISK J CAREY J COX M AHMAD B ANGUS E CAMPBELL H FIELDS D CROSWELL M BASHA K CHUNG P SCHOENHERR A MARCHIORI K MOBLEY M FRANCIS J KELLY J ETZWILER D HOLLANDER P CALLAHAN P CASTLE G BERGENSTAL R SPENCER M NELSON J BEZECNEY L ROETHKE C ORBAN M JACOBSON J CROWELL S WOLFSDORF J BEASER R GANDA O ROZENSWIEG J STEWART C HALFORD B FRIEDLANDER E TARSY D ARRIGG P SHARUK G SHAH S WU G CAVALLERANO J POOLE R CAVICCHI R FLEMING D MARCUS J GRIFFITHS C CAPELLA N NATHAN D LARKIN M GODINE J BRINK S NORMAN D MCKITRICK C DELAHANTY L ANDERSON E LOU P TAYLOR C CROS D LYNCH J MEINKES D FOLINO K LYON R SERVICE F SCHMIDT A RIZZA R ZIMMERMAN B SCHWENK W MORTENSEN J ZIEGLER G LUCAS A HANSON N PACH J WOODWICK R TACKMANN R SUAREZ G LEBARRON K SHUMANN M LIEN M COLWELL J MAYFIELD R PICKETT J WOOD D CHITWOOD M BILLINGS D DABNEY Y BUSE J KING L VALE S THOMPSON T BOHM B LYONS T HERMAYER K RICE A MOLITCH M SCHAEFER B JOHNSON C LYONS J METZGER B COHEN B NISHIDA T PARQUE K YUSIM V MOORE M DINEEN K STAHL J RICHINE L WEINBERG D LOOSE I KUSHNER M JAMPOL L MORRISON A TILDESLEY H JALBERT A LEUNG S BEGG I JOHNSON D KENNEDY T MEADOWS G KOLTERMAN O LORENZI G JONES K GOLDBAUM M GRANT I SWENSON M REED R KADLEC K GIOTTA M KIRSCH L ZIETLER R SIVITZ W SCHROTT H HOFFMAN R MACINDOE J KRAMER J BAYLESS M OLSON N TINDAL B SNETSELAAR L MUELLER D SWARTZENDRUBER J KOWARSKI A LEVIN P OSTROWSKI D YOUNGHYMAN D CHALEW S BARLOW M HYLTON J LAKHANPAL V ELMAN M BUIE W BLUM S WEINER B MACE B MILLAR M GREENE D FLOYD J MARTIN C BENNETT S LASICHAK A VINE A ALBERS J SANDFORD T LOFTIN J STEVENS M ELNER S DUNN F HENRY D BANTLE J BALLES M KENNEDY W KHAN M MECH M OLSON J KWONG C MCKENZIE L RAMSAY R WARHOL R ROBINER W KNOBLOCK W GOLDSTEIN D HALL M BURNS T KLACHKO D GIANGIACOMO J RAWLINGS S ASTON L ENGLAND J WIEDMEYER H DAUGHERTY M LIGHTFOOT M WILSON R WILSON R BLINDER K GASH L GARDNER D GRIFFING G BROWNLEEDUFFECK M PALMER NR CONWAY R SCHADE D JOHANNES C REIDY R BICKNELL J VOGEL A DRUMM D JONES N BOYLE P CANADY J NICKELL D CROFTON F BAKER L ILVESCORRESSEL P SCHWARTZ S BRAUNSTEIN S MCBRIDE J BRUCKER A RENDLE L BROWN M SLADKY J MASACKCAREY B LAWLEY D NYBERG W WEENEY L SANBURG E BYRD S AGUADO E MULHOLLAND N CAHN D SUSCAVAGE M DRASH A WESCHE J BRATKOWSKI M BECKER D ARSLANIAN S DOFT B FINEGOLD D LOBES L RINKOFF J WARNICKI J CURTIN D STEINBERG D VAGSTAD G RYAN C HARRIS F STERANCHAK L ARCH J KELLY K OLSEN K OSTROSKA P GUILIANI M GOOD M WILLIAMS T CAMPBELL A SHIPE C FLAVIA P CONWIT R MALONE J MCMILLIAN D GROVE N BABIONE L DECLUE T PAVAN P KORTHALS J SOLC H MANGIONE A KITABCHI A TAYLOR L BERTORINI T BURGHEN G FISHER J HUGHES T LINN J MEYER D MURPHY W JUSTICE M SHERMAN A WRIGHT L MURPHY L RICKS H RASKIN P STROWIG S BASCO M CERCONE S RAMIREZ L ANAND R WILSON C GREENLEE R ZINMAN B BARNIE A EHRLICH R DANEMAN D PERLMAN K LEITER L DEVENYI R MORTIMER C GORDON A FERGUSON R CAMELON K SIMKIN S LITTLEFIELD C RODIN G HARTLEY K KWAN J GNANAPANDITHEN D ROGERS S MCLEAN S MACKEEN L MILLER C MANDELCORN M NELLIS P RUTTAN L WILSONSMITH D PALMER J GINSBERG J KINYOUN J DOERR H MAUSETH R SWEENEY K OTTINGHAM L THOMSON L GREENBAUM C SAMESHIMA L HIRSCH I FARKASHIRSCH R ROSENBAUM G RUBNER N BROWN T KRAFT G BROECKEL J KARLSEN M KHAKPOUR D RAMIREZ M DUPRE J RODGER N COLBY P HRAMIAK I JENNER M CANNY C BROWN W SMITH T HARTH J BONDY S BEATH S MCCABE S GOUCHIE C LORENZ R LIPPS J MCRAE J MAY J MAY M CAMPBELL P FEMAN S KILROY A PULLIAM C SCHLUNDT D JANNASCH K DAVIS D SANTIAGO J WHITE N LEVANDOSKI L MCGILL J BUBB J OLK R NOETZEL M BONIUK I GRAND M KACIZAK R ORT E NOBEL G BODNER J DAHL J BILYEU P THOMAS M BLANK J SCHMIDT L STRASSBURG Y WALTERS C WILLIAMS D RODRIGUEZ P ERICKSON M HEDRICK S BREEDING L TAMBORLANE W AHERN J SHERWIN R GATCOMB P STOESSEL K HELD N EBERSOLE J SCANLON I CROFFORD O LACHIN J CLEARY P THOMPSON D KENNY D LAN S LAN G BRENNEMAN A OWEN W BACKLUND J ADAMS K ARNOLD D CAMPANELL R LORING N SCHEIRER P JANIFER N LAMAS D DUNEGAN C ATLURI H WILLIAMS C ABDULBAAQIY S PAKALAPATI S YALAMANCHILI V HO S FRIEDMAN R MCNANEY B GIVENS J COLACO Y JENIFER M OSBORNE R ZELL V YOUNG J KASSOFF A HEATON R DORMAN J SPIELMAN R KLEIN R SIEBERT C BEVERLY D SHORES S STECKLEIN L PIKE T PFEIFFER M SCHUMER M MORAN M FARQUHAR J WIEDMEYER H HUBBARD L MAGLI Y THOMAS S ONOFREY J JENSEN K BROTHERS R ANSAY S ARMSTRONG J BADAL D
Citation: H. Shamoon et al., IMPLEMENTATION OF TREATMENT PROTOCOLS IN THE DIABETES CONTROL AND COMPLICATIONS TRIAL, Diabetes care, 18(3), 1995, pp. 361-376
SUBCUTANEOUS ADMINISTRATION OF AC-137, A HUMAN AMYLIN ANALOG, REDUCESPOSTPRANDIAL HYPERGLYCEMIA (PPH) IN SUBJECTS WITH TYPE-I DIABETES-MELLITUS
Authors: KOLTERMAN O PETERSON J GOTTLIEB A
Citation: O. Kolterman et al., SUBCUTANEOUS ADMINISTRATION OF AC-137, A HUMAN AMYLIN ANALOG, REDUCESPOSTPRANDIAL HYPERGLYCEMIA (PPH) IN SUBJECTS WITH TYPE-I DIABETES-MELLITUS, Diabetes, 44, 1995, pp. 57-57
INTRAVENOUS (IV) INFUSION OF THE HUMAN AMYLIN ANALOG, AC-137, REDUCESPOSTPRANDIAL HYPERGLYCEMIA (PPH) IN SUBJECTS WITH TYPE-I DIABETES-MELLITUS RECEIVING ORAL NUTRIENTS BUT NOT IV GLUCOSE
Authors: KOLTERMAN O ORGAN K GOTTLIEB A
Citation: O. Kolterman et al., INTRAVENOUS (IV) INFUSION OF THE HUMAN AMYLIN ANALOG, AC-137, REDUCESPOSTPRANDIAL HYPERGLYCEMIA (PPH) IN SUBJECTS WITH TYPE-I DIABETES-MELLITUS RECEIVING ORAL NUTRIENTS BUT NOT IV GLUCOSE, Diabetes, 44, 1995, pp. 127-127
THE EFFECT OF INTENSIVE DIABETES TREATMENT ON THE PROGRESSION OF DIABETIC-RETINOPATHY IN INSULIN-DEPENDENT DIABETES-MELLITUS - THE DIABETESCONTROL AND COMPLICATIONS TRIAL
Authors: SHAMOON H DUFFY H FLEISCHER N ENGEL S SAENGER P STRELYZN M LITWAK M WYLIEROSETT J FARKASH A GEIGER D ENGEL H FLEISCHMAN J POMPI D GINSBERG N GLOVER M BRISMAN M WALKER E THOMASUNIS A GONZALEZ J GENUTH S DAHMS W BROWN E PUGSLEY P MAYER L KERR D LANDAU B SINGERMAN L RICE T NOVAK M SMITHBREWER S MCCONNELL J DROTAR D WOODS D LITVENE M KATIRJI B BROWN C CAMPBELL R RICHARDSON M LACKAYE M LEVY B CHANG S HEINHEINEMANN M BARRON S ASTOR L LEBECK D BRILLON D DIAMOND B VASILASDWOSKIN A BRISMAN M LAURENZI B FOLDI N RUBIN M WHITEHOUSE F KAHKONEN D KRUGER D FACHNIE J FISK J CAREY J COX M AHMAD B ANGUS E CAMPBELL H FIELDS D CROSWELL M BASHA K CHUNG P SCHOENHERR A MARCHIORI K MOBLEY M FRANCIS J KELLY J ETZWILER D HOLLANDER P CALLAHAN P CASTLE G BERGENSTAL R SPENCER M NELSON J BEZECNEY L ROETHKE C ORBAN A JACOBSEN A CROWELL S WOLFSDORF J BEASER R GANDA O ROZENSWIEG J STEWART C HALFORD B FRIEDLANDER E TARSY D ARRIGG P SHARUK G SHAH S WU G CAVALLERANO J POOLE R CAVICCHI R FLEMING D MARCUS J GRIFFITHS C CAPPELLA N NATHAN D LARKIN M GODINE J BRINK S NORMAN D MCKITRICK C DELAHANTY L ANDERSON E LOU P TAYLOR C CROS D LYNCH J MEINKES D FOLINO K LYON R SCHMIDT A RIZZA R ZIMMERMAN B SCHWENK W MORTENSON J ZIEGLER G LUCAS A HANSON N PACH J WOODWICK R TACKMANN R SUAREZ G LEBARRON K SHUMANN M LIEN M COLWELL J MAYFIELD R PICKETT J WOOD D CHITWOOD M BILLINGS D DABNEY Y BUSE J KING L VALE S THOMPSON T BOHM B LYONS T HERMAYER K RICE A MOLITCH M SCHAEFER B JOHNSON C LYONS J METZGER B COHEN B NISHIDA T PARQUE K YUSIM V MOORE M DINEEN K STAHL J RICHINE L WEINBERG D LOOSE I KUSHNER M JAMPOL L MORRISON A TILDESLEY H JALBERT A LEUNG S BEGG I JOHNSON D KENNEDY T MEADOWS G KOLTERMAN O LORENZI G JONES K GOLDBAUM M GRANT I SWENSON M REED R KADLEC K GIOTTA M LYON R KIRSCH L ZIETLER R SIVITZ W SCHROTT H HOFFMAN R MACINDOE J KRAMER J BAYLESS M OLSON N TINDAL B SNETSELAAR L MUELLER D SWARTZENDRUBER A KOWARSKI A LEVIN P OSTROWSKI D YOUNGHYMAN D CHALEW S BARLOW M HYLTON J LAKHANPAL V ELMAN M BUIE W BLUM S WEINER B MACE B MILLAR M GREENE D FLOYD J MARTIN C BENNETT S LASICHAK A VINE A ALBERS J SANDFORD T LOFTIN J STEVENS M ELNER S DUNN F HENRY D BANTLE J BALLES M KENNEDY W KHAN M MECH M OLSON J KWONG C MCKENZIE L RAMSAY R WARHOL R ROBINER W KNOBLOCK W GOLDSTEIN D HALL M BURNS T KLACHKO D GIANGIACOMO J RAWLINGS S ASTON L ENGLAND J WIEDMEYER H DAUGHERTY M LIGHTFOOT M WILSON R WILSON R BLINDER K GASH L GARDNER D GRIFFING G BROWNLEEDUFFECK M PALMER NR CONWAY R SCHADE D JOHANNES C REIDY R BICKNELL J VOGEL A DRUMM D JONES N BOYLE P CANADY J NICKELL D CROFTON F BAKER L ILVESCORRESSEL P SCHWARTZ S BRAUNSTEIN S MCBRIDE J BRUCKER A RENDLE L BROWN M SLADKY J MASCHAKCAREY B LAWLEY D NYBERG W WEENEY L SANDBURG E BYRD S AGUADO E MULHOLLAND N CAHN D SUSCAVAGE M DRASH A WESCHE J BRATKOWSKI M BECKER D ARSLANIAN S DOFT B FINEGOLD D LOBES L RINKOFF J WARNICKI J CURTIN D STEINBERG D VAGSTAD G RYAN C HARRIS F STERANCHAK L ARCH J KELLY K OLSEN K OSTROSKA P GUILIANI M GOOD M WILLIAMS T CAMPBELL A SHIPE C FLAVIA P CONWIT R MALONE J MCMILLIAN D GROVE N BABIONE L DECLUE T PAVAN P KORTHALS J SOLE H MANGIONE A KITABCHI A TAYLOR L BERTORINI T BURGHEN G FISHER J HUGHES T LINN J MEYER D MURPHY W JUSTICE M SHERMAN A WRIGHT L MURPHY L RICKS H RASKIN P STROWIG S BASCO M CERCONE S RAMIREZ L ANAND R WILSON C GREENLEE R ZINMAN B BARNIE A EHRLICH R DANEMAN D PERLMAN K LEITER L DEVENYI R MORTIMER C GORDON A FERGUSON R CAMELON K SIMKIN S LITTLEFIELD C RODIN G HARTLEY K KWAN J GNANAPANDITHEN D ROGERS S MCLEAN S MACKEEN L MILLER C MANDELCORN M NELLIS P RUTTAN L WILSONSMITH D PALMER J GINSBERG J KINYOUN J DOERR H MAUSETH R SWEENEY K OTTINGHAM L THOMSON L GREENBAUM C SAMESHIMA I HIRSCH I FARKASHIRSCH R ROSENBAUM G RUBNER N BROWN T KRAFT G BROECKEL J KARLSEN M KHAKPOUR D RAMIREZ M DUPRE J RODGER N COLBY P HRAMIAK I JENNER M CANNY C BROWN W SMITH T HARTH J BONDY S BEATH S MCCABE S GOUCHIE C LORENZ R LIPPS J MCRAE J MAY J MAY M CAMPBELL P FEMAN S KILROY A PULLIAM C SCHLUNDT D JANNASCH K DAVIS D SANTIAGO J WHITE N LEVANDOSKI L MCGILL J BUBB J OLK R NOETZEL M BONIUK I GRAND M KACIZAK R ORT E NOBEL G BODNAR J DAHL J BILYEU P THOMAS M BLANK J SCHMIDT L STRASSBURG Y WALTERS C WILLIAMS D RODRIGUEZ P ERICKSON M HEDRICK S BREEDING L HOFFMEYER G TAMBORLANE W AHERN J SHERWIN R GATCOMB P STOESSEL K HELD N EBERSOLE J SCANLON I CROFFORD O LACHIN J CLEARY P THOMPSON D KENNY D LAN S LAN G BRENNEMAN A OWEN W BACKLUND J ADAMS K ARNOLD D CAMPANELL R LORING N SCHEIRER P BECKER D JANIFER N LAMAS D DUNEGAN C ATLURI H WILLIAMS C ABDULBAAQIY S PAKALAPATI S YALAMANCHILI V HO S FRIEDMAN R MCNANEY B GIVENS J COLACO Y JENIFER M OSBORNE R ZELL V YOUNG J SIEBERT C BEVERLY D SHORES S STECKLEIN L PIKE T PFEIFFER M SCHUMER M MORAN M FARQUHAR J DAVIS M HUBBARD L MAGLI Y THOMAS S ONOFREY J JENSEN K BROTHERS R ANSAY S ARMSTRONG J BADAL D VANDERHOOFYOUNG M ESSER B
Citation: H. Shamoon et al., THE EFFECT OF INTENSIVE DIABETES TREATMENT ON THE PROGRESSION OF DIABETIC-RETINOPATHY IN INSULIN-DEPENDENT DIABETES-MELLITUS - THE DIABETESCONTROL AND COMPLICATIONS TRIAL, Archives of ophthalmology, 113(1), 1995, pp. 36-51
FIRST ADMINISTRATION TO MAN OF THE HUMAN AMYLIN ANALOG TRIPRO-AMYLIN
Authors: MOYSES C KOLTERMAN O NUTTALL A MANT T
Citation: C. Moyses et al., FIRST ADMINISTRATION TO MAN OF THE HUMAN AMYLIN ANALOG TRIPRO-AMYLIN, Diabetologia, 37, 1994, pp. 10000072-10000072
AMYLIN AGONIST, AC-137, REDUCES POSTPRANDIAL HYPERGLYCEMIA IN SUBJECTS WITH INSULIN-DEPENDENT DIABETES-MELLITUS (IDDM)
Authors: KOLTERMAN O GLOTTLIEB A MOYSES C
Citation: O. Kolterman et al., AMYLIN AGONIST, AC-137, REDUCES POSTPRANDIAL HYPERGLYCEMIA IN SUBJECTS WITH INSULIN-DEPENDENT DIABETES-MELLITUS (IDDM), Diabetes, 43, 1994, pp. 10000078-10000078
INFUSION OF AMYLIN AGONIST, AC-0137, REDUCES POSTPRANDIAL HYPERGLYCEMIA IN SUBJECTS WITH TYPE-1 DIABETES (IDDM)
Authors: KOLTERMAN O KISICKI JC PELTIER L GOTTLIEB A MOYSES C
Citation: O. Kolterman et al., INFUSION OF AMYLIN AGONIST, AC-0137, REDUCES POSTPRANDIAL HYPERGLYCEMIA IN SUBJECTS WITH TYPE-1 DIABETES (IDDM), Clinical research, 42(1), 1994, pp. 10000087-10000087
Risultati: 1-25 | 26-26